weight management
Gan & Lee Doses First Patient in Oral GLP-1 Pill Trial
Gan & Lee Pharmaceuticals Co., Ltd. (SSE: 603087.SH) announced on September 9 that the first participant has been dosed in a first-in-human Phase 1 study of GZC8072, an experimental once-weekly oral peptide GLP-1 receptor agonist, marking the compound’s formal entry into human testing. This is an early, safety-focused milestone, not an efficacy result, and no…
Ascletis’ ASC30 Enters Phase III After Mixed Phase II Data
Ascletis Pharma Inc. (HKEX: 1672) announced on August 30 that the first participant has been dosed in its global Phase III program for ASC30, an investigational once-daily oral small molecule GLP-1 receptor agonist for chronic weight management. The program consists of two pivotal trials, AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450), expected to enroll roughly 4,600 participants…
